Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.44 |
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124522 | 0.83 | MGLL (0.50) | MGLLTRPV1CNR1POLBFAAH | |
| SCHEMBL5129226 | 0.81 | MGLL (0.50) | MGLLTRPV1CNR1GRIK1FAAH | |
| SCHEMBL5123741 | 0.79 | TRPV1 (0.58) | MGLLTRPV1CNR1GRIK1 | |
| SCHEMBL5123680 | 0.79 | MGLL (0.50) | MGLLTRPV1CNR1GRIK1DGAT1 | |
| SCHEMBL5974491 | 0.77 | ACHE (0.40) | TRPV1 | |
| SCHEMBL2734510 | 0.76 | TRPV1 (0.57) | MGLLTRPV1CNR1GRIK1DGAT1 | |
| SCHEMBL5139603 | 0.76 | TRPV1 (0.70) | TRPV1 | |
| SCHEMBL2734355 | 0.75 | TRPV1 (0.61) | MGLLTRPV1CNR1 | |
| SCHEMBL206358 | 0.75 | TRPV1 (0.58) | MGLLTRPV1CNR1DGAT1 | |
| SCHEMBL2734509 | 0.74 | TRPV1 (0.64) | TRPV1CNR1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1678123-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040100-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | NMUR1, GPR17, NMUR2 | MGLL 4480/4885TRPV1 10/4885CNR1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.